Cisatracurium
Cisatracurium Besylate (cisatracurium) is a small molecule pharmaceutical. Cisatracurium was first approved as Nimbex on 1995-12-15.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Nimbex (generic drugs available since 2012-02-03)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cisatracurium | ANDA | 2021-06-09 |
| cisatracurium besylate | ANDA | 2024-08-29 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
146 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuromuscular blockade | D019148 | — | — | — | 1 | — | 7 | 9 | 17 |
| Acute lung injury | D055371 | EFO_0004610 | — | 1 | 2 | 2 | 3 | 6 | 14 |
| Anesthesia | D000758 | — | — | — | — | — | 6 | 8 | 14 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | 1 | 2 | 2 | 3 | 5 | 13 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | 1 | 2 | 2 | 3 | 5 | 13 |
| General anesthesia | D000768 | — | — | — | — | 1 | 2 | 8 | 11 |
| Postoperative pain | D010149 | — | G89.18 | — | — | — | 3 | 4 | 7 |
| Emergence delirium | D000071257 | — | — | 1 | — | — | 2 | 4 | 7 |
| Delirium | D003693 | — | R41.0 | 1 | — | — | 1 | 4 | 6 |
| Delayed emergence from anesthesia | D055191 | — | — | — | — | — | 4 | 2 | 6 |
Show 63 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fasciculation | D005207 | — | R25.3 | — | — | 2 | — | 1 | 3 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 1 | — | 1 | 2 |
| Meningioma | D008579 | EFO_0003098 | D32.9 | — | — | 1 | — | — | 1 |
| Myalgia | D063806 | HP_0003326 | M79.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Muscle hypotonia | D009123 | HP_0001319 | — | — | 1 | — | — | 3 | 4 |
| Hypothermia | D007035 | HP_0002045 | T68 | — | 2 | — | — | 2 | 4 |
| Covid-19 | D000086382 | — | — | — | 1 | — | — | 2 | 3 |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | 1 | — | — | — | 1 |
| Spondylolisthesis | D013168 | EFO_0007493 | M43.1 | — | 1 | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | — | — | — | 1 |
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | — | 1 | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | — | — | — | 1 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | — | 1 | — | — | — | 1 |
| Intraocular pressure | D007429 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypoxia | D000860 | HP_0012418 | R09.02 | 1 | — | — | — | 1 | 2 |
| Femur head necrosis | D005271 | — | — | 1 | — | — | — | — | 1 |
| Necrosis | D009336 | — | — | 1 | — | — | — | — | 1 |
| Respiratory tract diseases | D012140 | — | — | 1 | — | — | — | — | 1 |
| Respiration disorders | D012120 | — | J00-J99 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intravenous anesthesia | D000771 | — | — | — | — | — | — | 6 | 6 |
| Intratracheal intubation | D007442 | — | — | — | — | — | — | 3 | 3 |
| Epidural anesthesia | D000767 | — | — | — | — | — | — | 2 | 2 |
| Aortic dissection | D000784 | — | I71.0 | — | — | — | — | 2 | 2 |
| Conduction anesthesia | D000765 | — | — | — | — | — | — | 2 | 2 |
| Thoracic surgical procedures | D019616 | — | — | — | — | — | — | 2 | 2 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | — | — | — | 2 | 2 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | — | 2 | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 2 | 2 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 2 | 2 |
Show 64 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cisatracurium |
| INN | cisatracurium besilate |
| Description | Cisatracurium besylate is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium besylate. Commercial preparations of atracurium are mixtures of 10 stereoisomers, of which cisatracurium generally constitutes about 15%. Cisatracurium besylate is about 3 times more potent than the mixture of atracurium isomers as a neuromuscular blocking agent, and is used as a muscle relaxant for endotracheal intubation, to aid controlled ventilation, and in general anaesthesia. It has a role as a muscle relaxant and a nicotinic antagonist. It is a quaternary ammonium salt, an atracurium besylate and an organosulfonate salt. It contains a cisatracurium. |
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives: neuromuscular blocking agents |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC |
Identifiers
| PDB | — |
| CAS-ID | 96946-41-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201248 |
| ChEBI ID | — |
| PubChem CID | 62886 |
| DrugBank | DB00565 |
| UNII ID | 80YS8O1MBS (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,138 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,028 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use